Abstract Body

The goals of hepatitis B virus (HBV) treatment are to: 1) achieve sustained suppression of HBV replication, 2) decrease liver injury and 3) prevent cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death.  Currently available FDA-approved therapies have been able to deliver on each of these clinical goals, using well-tolerated nucleos(t)ide analogues with high barriers to resistance. However, they are limited in their ability to yield functional cure (loss of HBsAg with or without anti-HBs seroconversion). Hence, there remains a large unmet clinical need.

The ultimate clinical goal is to achieve functional cure of HBV with a finite course of treatment. However, there are many challenges to HBV functional cure. Most importantly, like HIV, HBV has a latent form, covalent closed circular DNA (cccDNA), a highly stable episomal form of the HBV genome that serves as the template for new HBV transcription in the nucleus. Moreover, a fraction of HBV DNA is also integrated into the host genome, and there is evidence that a portion of integrated HBV DNA, particularly HBsAg, can be translated. These stable forms are largely untouched by current therapies. There is also evidence that in chronic hepatitis B (CHB), the adaptive virus-specific immune response becomes exhausted, further contributing to chronicity.

The latest therapies in the pipeline seek to achieve HBsAg loss using approaches that target other, discrete steps in the HBV lifecycle as well as modulate the immune environment essential for clearance. Novel antiviral therapies in clinical development include entry inhibitors, capsid assembly modifiers to block assembly and possibly replenishment of cccDNA, RNA interference (siRNA) to block viral protein production, and nucleic acid polymers to block HBsAg release. Immunomodulatory therapies include strategies both to stimulate innate and adaptive responses and to block inhibitory pathways. The targeting of the adaptive immune response may be particularly critical, since functional cure observed during spontaneous resolution of acute hepatitis B (sAg loss, sAb seroconversion) is heavily dependent on a brisk T cell response. In this regard, success using an anti-PD-1 approach has been observed in early studies of these agents in chronic hepatitis B. It is likely that some combination of these novel treatment approaches and existing approved agents will be necessary to achieve functional cure.